Clinical Trials Logo

Citation(s)

  •   Bavishi C, Maddox TM, Messerli FH
    Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282. No abstract available.
  •   Patel AB, Verma A
    COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812. No abstract available.
  •   Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG
    Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 2020 Nov;81(7):768-770. doi: 10.1002/ddr.21679. Epub 2020 May 1.
  •   Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G
    Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clin Proc. 2020 Jun;95(6):1222-1230. doi: 10.1016/j.mayocp.2020.03.026. Epub 2020 Apr 4.
  •   Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD
    Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30. No abstract available.

Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19

Details for clinical trial NCT04510662